Immunitybio Inc annual net income for fiscal TTM was -$992 million, a decrease of 182.6% from -$351 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Net Income (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | ($992M) | ($351M) | ($414M) | ($583M) | ($417M) | ($347M) | ($222M) | ($66M) | ($96M) | ($96M) | ($121M) | ($237M) | ($6M) | ($2M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Net Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Net Income | ($230M) | ($633M) | ($62M) | ($67M) | ($93M) | ($130M) | ($59M) | ($86M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More IBRX metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All IBRX financial statements → Interactive IBRX charts →
About TickerBase · Data methodology & sources · Privacy · Terms